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How did the study come about?
The HIV/AIDS pandemic is a public health emergency
in many low and middle-income countries. Out of the
estimated 33.3 million people with HIV at the end of
2009, 22.5 million were in sub-Saharan Africa and the
majority of these were women.1 The introduction
in 1996 of combination anti-retroviral therapy (ART)
led to a substantial reduction in morbidity and mor-
tality in high-income countries.2,3 In more recent
years, efforts by governmental programmes such as
the President’s Emergency Program for AIDS Relief
(PEPFAR) and The Global Fund as well as non-
governmental programmes have resulted in the
scale-up of ART in resource-limited settings: at the
end of 2009, 5.25 million people were reported to be
receiving ART therapy in low- and middle-income
countries.1
Although still far from achieving universal cover-
age,1 the massive concerted scale-up of ART is unpre-
cedented in global health. The long-term outcomes of
ART in Africa and other regions are, however, not
well defined. Poor retention in care, limited access
to second-line ART regimens, co-infections and com-
orbidities of HIV infection, for example tuberculosis
and cancer, and the emergence of drug resistance
and toxicities are important challenges to long-term
programme effectiveness in resource-limited settings.7
The World Health Organization (WHO) advocates a
public health approach to ART in resource-limited set-
tings, to maximize benefit in a setting of low levels
of training for health-care workers, high patient bur-
den and limited availability of drugs. Key characteris-
tics include the standardization of first-line and
second-line ART regimens, simplified clinical decision-
making and standardized clinical and laboratory
monitoring.4–6
In 2005, the National Institute of Allergy and
Infectious Diseases (NIAID) sought applications for
a global consortium structured through regional cen-
tres to pool existing clinical and epidemiological
data on HIV-infected people, and particularly patients
on ART: the International epidemiological Databases
to Evaluate AIDS (IeDEA, see Figure 1 for logo).8
Funding of IeDEA has recently been extended to
2011–2016. The seven regions included in IeDEA are
North America, Caribbean/Central and South America,
Asia/Pacific and four regions in sub-Saharan Africa. A
Coordinating Centre (currently at RTI International,
NC, USA) provides logistical and data management
and harmonization support to the regional networks.
Two of the IeDEA cohorts have previously been
described in the journal.9,10 The objective of the pre-
sent report is to describe the four African IeDEA
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regions: West Africa, Central Africa, East Africa and
Southern Africa.
What does it cover?
The African networks of IeDEA aim to inform the
scale-up of ART in sub-Saharan Africa through clin-
ical and epidemiological research. The specific re-
search questions differ by region, but the objectives
are similar and cover all populations, including preg-
nant women, infants, children, adolescents and adult
patients. They can be summarized as follows:
(1) To provide robust evaluation of the delivery of
ART in children, adolescents and adults in sub-
Saharan Africa, with a focus on long-term pro-
gramme effectiveness and outcomes.
(2) To describe the long-term and temporal trends in
regimen durability and tolerability and to exam-
ine monitoring strategies.
(3) To describe important comorbidities and
co-infections of HIV infection, including malaria,
tuberculosis and cancer.
(4) To examine the pregnancy- and HIV-related out-
comes of women initiating ART during preg-
nancy and of infants exposed to HIV or ART in
utero.
(5) To develop and apply novel statistical methods to
deal with missing data, loss to follow-up, com-
peting risks and time-dependent confounding.
(6) To establish procedures to link the HIV cohort
data with other databases, at local or national
level, for example routine mortality data or tu-
berculosis and cancer registries.
Who is in the sample?
A total of 183 clinics providing ART in 17 countries in
sub-Saharan Africa participate in IeDEA’s four
African regions (Figure 2). Most sites are located in
urban areas, operate at the primary care level, are led
by nurses or clinical officers rather than physicians
and are part of the public health care system of the
country (Table 1). About two-thirds of sites have the
capacity to measure CD4 cell counts, and a third can
do HIV-1 RNA tests. Virtually all sites provide adher-
ence support to patients, screen and provide treat-
ment for tuberculosis. ART provision at most sites
started during or after 2004 with the exception of
several clinics in West Africa, which introduced ART
earlier. Figure 3 shows the cumulative number of
treatment sites and adult patients starting ART.
There has been a rapid increase in facilities and pa-
tients contributing data to IeDEA which is for the
most part due to rapid scale-up by a few countries
in each region. For example, South Africa and
Zambia in Southern Africa and Nigeria in West
Africa had the most rapid scale-up in their region.
All three contributing countries in East Africa have
expanded coverage. Central Africa faces unique chal-
lenges in that Rwanda was the only PEPFAR focus
country and other countries in the region have ex-
tremely weak health systems and government re-
sponses to the epidemic. Central Africa has had only
modest scale up of treatment and increases in the
research database are the result of active data collec-
tion and data system strengthening.
Patients are consecutively included as they initiate
HIV care at a participating clinic or programmes until
the capacity of the site is reached. At most sites, data
collection starts when a patient initiates ART; how-
ever, some programmes also collect data on patients
in the pre-ART period (not yet eligible for ART or
eligible but waiting to be treated). Data are stripped
of identifiers at the clinic level and all analysis is per-
formed with de-identified data. Given the use of
de-identified data, most patients are not individually
consented to participate. However, when additional
data is collected from patients outside of routine clin-
ical practice, informed consent is sought. All research
is overseen by Institutional Review Boards (IRBs) in
the countries where data are collected, and addition-
ally by IRBs with oversight over the analytical teams.
In West, East and Southern Africa data are obtained
from existing clinical databases. In Central Africa, the
study team created prospective cohorts as existing
health records were not sufficient for epidemiologic
research. Table 2 shows the characteristics of the
286 803 adult patients on ART recorded in the
African IeDEA databases as of the end of 2010. In
all regions, most patients were 30- to 40-years old,
female, and started ART with advanced immune-
deficiency and advanced clinical stage (WHO stage
III or IV). A substantial minority of patients started
ART without a recent CD4 cell count, many patients
did not have a CD4 count measured around 6 months
and only few patients had viral load measurements at
baseline or 6 months. In all regions, the most com-
monly used first-line ART regimen was lamivudine
(3TC), stavudine (d4T) and nevirapine (NVP), and
the majority of patients were started on one of three
Figure 1 Logo of the IeDEA
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regimens (Table 3). The African IeDEA regions also
include smaller cohorts of paediatric patients, which
will be described in a separate report.
How often are patients followed
up and what is measured?
As IeDEA is based on routine clinical records, the pa-
tient follow-up reflects the standards of care in the
participating clinics. For most patients, visits are ini-
tially bi-monthly or monthly, and then drop to every
2–3 months as therapy is stabilized (Table 1). Clinics
have various methods for tracing patients who miss
visits including mobile phone calls/SMS or home
visits. Some sites also involve volunteers from
community-based organizations to track patients.
Patient tracing is clinic specific, and the methods
and capacity for tracing patients is heterogeneous
within the regions.
Most data are collected in the context of routine
care at baseline and each follow-up visit, including
socio-demographic data, contact details to facilitate
the tracing of patients, the date of starting ART,
type of treatment initiated, and, where available,
CD4 counts and HIV-1 plasma RNA levels at baseline
and during follow-up. The switching to second-line
ART regimens is recorded in all sites, and the reasons
for switching in some sites. Resistance testing is not
routinely available in any of the programmes, but is
Figure 2 Map of 183 ART facilities participating in the four African regions of the International epidemiological Databases
to Evaluate AIDS
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Table 1 Characteristics of 183 facilities providing ART in the African regions of the IeDEA
West
Africa
Central
Africa
East
Africa
Southern
Africa All regions (%)
No. of facilities 15 10 32 126 183 (100)
Location
Urban 15 8 18 69 110 (60.1)
Semiurban 0 2 10 20 32 (17.5)
Rural 0 0 4 37 41 (22.4)
Level of care
Primary 8 6 10 102 131 (71.6)
Secondary 0 3 15 15 33 (18.0)
Tertiary 7 1 7 4 19 (10.4)
Type of facility
Public 12 4 28 108 152 (83.1)
Private not for profit 3 6 4 12 25 (13.7)
Private for profit 0 0 0 6 6 (3.3)
Patient contributions to costs of care 1 0 1 71 74 (40.4)
Availability of laboratory tests
CD4 cell count 15 10 12 71 108 (59.0)
Total lymphocyte count 15 7 12 42 76 (41.5)
HIV-1 RNA 0 10 4 50 64 (35.0)
TST (tuberculin skin test) 15 0 2 64 81 (44.3)
Sputum smear 15 4 31 50 100 (54.6)
Culture for Mycobacterium tuberculosis 15 2 23 0 40 (21.9)
Chest X-ray 5 3 32 15 55 (30.1)
Other interventions and services
Nutritional support 0 10 32 69 111 (60.7)
Voluntary testing and counselling 15 10 32 62 119 (65.0)
Adherence support 15 10 32 123 180 (98.4)
Screening for Tb 0 9 32 126 167 (91.3)
Treatment for Tb 0 4 29 121 154 (84.2)
Visits after starting ART
Weekly 0 0 7 0 7 (3.8)
Two weekly 0 0 23 69 92 (50.3)
Monthly 15 10 2 58 85 (46.5)
Visits when stable on ART
Monthly 15 1 13 49 78 (42.6)
Every 2 months 0 0 10 9 19 (10.4)
Every 3 months 0 9 9 69 87 (47.5)
Tracing of patients not returning
Phone calls 8 10 26 125 157 (92.4)
Home visits 2 10 29 88 129 (70.5)
Community-based organizations 0 10 0 42 52 (28.4)
Other 0 0 4 6 10 (5.5)
No routine tracing 0 0 0 27 27 (14.8)
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done at some sites in a research context. Important
comorbidities and co-infections, including malaria, tu-
berculosis and cancer, are recorded in most sites.
A survey of sites is conducted regularly to collect
data on (i) level of care (primary, secondary, tertiary),
points of entry to programme, typical travel time of
patients to clinic, costs to patients; (ii) availability of
laboratory tests and radiology, availability of other
services (family planning, nutritional support), level
of staffing; (iii) eligibility and preparation of patients
for ART, waiting times, first-line and second-line ART
regimens, and monitoring of ART; (iv) follow-up and
assessment of adherence, transfers, tracing of patients
lost to follow-up, ascertainment of deaths; (v) and the
diagnosis and management of HIV-associated compli-
cations, including tuberculosis, cryptococcus, cyto-
megalovirus and malaria.
Linkages to routine data sources have been con-
ducted in the Republic of South Africa. For example,
cohort data were linked with the database of the
South African National Health Laboratory Services
(NHLS) to obtain additional CD4 cell counts, which
were not recorded in the HIV database.11 Similarly,
cohorts were linked to the routine mortality data to
improve ascertainment of deaths.11–13 Linkages with
cancer registries are under way.
What is attrition like?
Retention in care is an important issue for the African
sites participating in IeDEA, and for treatment pro-
grammes in resource-limited settings in general.14,15,16
In a recent IeDEA study of 11 treatment programmes
in 10 countries (Botswana, Coˆte d’Ivoire, Kenya,
Malawi, Rwanda, Senegal, South Africa, Uganda,
Zambia, Zimbabwe) loss to follow-up at 1 year
ranged from 2.8% to 28.7%. In this study, a patient
was considered lost to follow-up if the last visit was
49 months before the closure date for that site, with
the closure date defined as the most recent visit date
recorded in the database.17 A study from the Central
African region found that rates of lost to follow-up,
defined as not attending the clinic for six months or
longer, were 35% in the Democratic Republic of
Congo, 38% in Burundi and 27% in Cameroon.18
Using the same definition, an analysis of IeDEA
West Africa found that among patients with at least
one follow-up visit 20% of patients were lost to
follow-up at 1 year.19 The most appropriate definition
of loss to follow-up was examined in the Ministry of
Health-Centre for Infectious Disease Research in
Zambia (MoH-CIDRZ) programme, the largest cohort
in the Southern African region.20 The definition that
minimized misclassification was ‘at least 2 months
late for the last scheduled clinic appointment’.20
Efforts to standardize definitions within and across
IeDEA regions are now under way.21
The successful treatment of individual patients and
the monitoring and evaluation of ART programmes
both depend on regular and complete patient
follow-up. Programmes with high rates of loss to
follow-up and poor ascertainment of deaths in pa-
tients lost will underestimate mortality of all patients
starting ART. A meta-analysis of studies tracing pa-
tients lost to follow-up found that these patients ex-
perience high mortality22 compared with patients
remaining in care.23 Standard survival analyses,
which censors lost patients, will underestimate overall
clinic mortality as censored mortality is estimated
from the mortality of patients remaining in care.
Analyses of the determinants of survival may also
be biased, as empirically demonstrated in an analysis
from East Africa.24
IeDEA investigators developed approaches for more
accurate and less biased measurements of mortality
and determinants of survival. East Africa used meth-
ods based on the concept of ‘double sampling’25,26 to
adjust mortality estimates based not on those in care,
but instead on a subset of patients lost to follow-up
whose status was ascertained through extensive tra-
cing efforts.27 In another analysis, the same region
used patient tracing data to construct weighted
Kaplan–Meier curves, which assign the proper
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Figure 3 Cumulative number of treatment sites (a) and
cumulative number of patients starting antiretroviral
therapy (b) in the four African regions of the IeDEA
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weight to deaths discovered through patient out-
reach.28 A study based on data from three regions
filled the missing survival times of patients lost to
follow-up by multiple imputation, using estimates of
mortality from studies that traced patients lost to
follow-up.29 The Southern Africa region extended
these methods to create a simple nomogram and
web calculator (see www.iedea-sa.org) which can be
used by programme managers to correct mortality es-
timates for loss to follow-up.17
Key findings and publications
Here, we provide an indicative summary of some of
the major research themes. A complete list of publi-
cations and presentations from the different IeDEA
regions can be found at www.iedea-hiv.org.
Mortality and retention in care in children and
adults are central to evaluating ART programmes in
resource-limited settings, and have been the focus of
several analyses. Analyses have considered the first
year of ART,15,17,30–33 or the first few years,34–36 and
documented high early mortality and loss to
follow-up (LTFU), and very high mortality in patients
waiting to be treated.11 Significant for programme
evaluation, IeDEA Southern Africa found that esti-
mates of adult mortality in South Africa substantially
increased after data from the Free State Province,11
the Khayelitsha programme,12 or the Themba Lethu
Clinic cohort13 were linked with the South African
death registry and deaths among patients LTFU
included. Analyses of the South African IeDEA data
contributed to evaluating the National Antiretroviral
Table 2 Baseline characteristics of patients starting antiretroviral therapy at sites participating in the African regions of the
IeDEA
West Africa Central Africa East Africa Southern Africa
Total No. of patients 33 368 8902 60 137 184 386
No. of female 21 057 (63.1) 6252 (70.2) 40 531 (67.4) 116 349 (63.1)
Gender unknown 145 (0.43) 3 (0.03) 303 (0.50) 4 (0.00)
Age (years) 40.6 (34.1–42.8) 38 (32–46) 35.8 (30.2–42.6) 29 (24–36)
Unknown 355 (1.1) 7 (0.08) 3680 (6.1) 564 (0.31)
Weight (kg) 57 (49–65) 60 (52–70) 55.4 (49.0–62.5) 55 (48–62)
Not measured 3367 (10.1) 27 (0.30) 2937 (4.9) 15 107 (8.2)
Height (cm) 165 (159–170) 164 (159–170) 164.5 (159.5–170.5) 164.0 (158–170)
Not measured 12 340 (37.0) 43 (0.48) 21 964 (36.5) 71 141 (38.6)
Advanced clinical stage
(WHO stage III/IV)
12 713 (38.1) 5990 (67.3) 32 237 (53.6) 102 178 (55.4)
WHO stage unknown 6271 (18.8) 29 (0.33) 4973 (8.3) 22 702 (12.3)
Active Tuberculosis 2042 (6.1) 1892 (21.3) 14 326 (23.8) 11 771 (6.4)
Unknown 7517 (22.5) 0 0 128 190 (69.5)
Haemoglobin (g/dl) 10.2 (9.0–11.6) 11.5 (9.9–13.2) 11.1 (9.5–12.7) 11 (9.4–12.3)
Not measured 10 506 (31.5) 4197 (47.2) 34 770 (57.8) 72 340 (39.2)
CD4 count (cells/ml)a
At baseline 145 (62–237) 211 (110–335) 130 (54–211) 126 (62–192)
Not measured 8245 (24.7) 3070 (34.50) 19 590 (32.6) 39 694 (21.5)
At 6 month 274 (173–402) 318 (213–481) 254 (162–380) 253 (169–362)
Not measured 18 555 (55.6) 8428 (94.7) 38 570 (64.1) 103 791 (56.3)
HIV–1 RNA (log copies/ml)a
At baseline 5.11 (4.07–5.63) 1.97 (1.70–2.40) 5.12 (3.94–5.54) 11.14 (9.74–12.39)
Not measured 32 175 (96.4) 8513 (95.6) 59 819 (99.5) 155 906 (84.6)
At 6 month 2.48 (2.00–2.48) 2.0 (2.00–2.00) 2.60 (2.60–2.60) 4.79 (3.53–5.56)
Not measured 32 114 (96.2) 8880 (99.7) 59 689 (99.3) 155 135 (84.1)
No. of patients or median (interquartile range) are shown.
aBaseline was defined as the measurement closest to the start of therapy within a window of 3 months before and 1 week after
starting therapy. At 6 month was defined as the measurement closed to 6 months within a window of 3–9 months.
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Treatment Programme, both for adults32,33 and
children.35
Using data for adult patients who started ART in
four scale-up programmes in Coˆte d’Ivoire, South
Africa, and Malawi from 2004 to 2007, IeDEA inves-
tigators developed two prognostic models to estimate
the probability of death in patients starting ART in
sub-Saharan Africa.23 One model with CD4 cell
count, clinical stage, bodyweight, age and sex (CD4
count model); and one that replaced CD4 cell count
with total lymphocyte count and severity of anaemia
(total lymphocyte and haemoglobin model), because
CD4 cell count is not routinely available. Probability
of death at 1 year ranged from 0.9% to 52.5% with the
CD4 model, and from 0.9% to 59.6% with the total
lymphocyte and haemoglobin model. Both models ac-
curately predicted early mortality in patients starting
ART in sub-Saharan Africa compared with observed
data. A web calculator is available at www.iedea-sa
.org.
The durability of first-line ART regimens and
switching to second-line ART has been another
focus. A recent analysis of the United States Agency
for International Development–Academic Model
Providing Access to Healthcare (USAID-AMPATH)
partnership, a large treatment programme in western
Kenya, found that ART discontinuation was more
common among patients with advanced disease and
those receiving a zidovudine-containing regimen.37 A
further analysis of data from all four African IeDEA
regions found that many patients did not switch to a
second-line regimen, despite developing treatment
failure.38 Unsurprisingly, these patients experienced
high mortality.38
IeDEA has also supported public health programmes
through analyses for UNAIDS or WHO. African IeDEA
data were used to parameterize the Spectrum projec-
tion package, used to estimate the impact of HIV in
low and middle-income countries.39 Similarly, IeDEA
data were used to evaluate different sampling strate-
gies to assess programmatic indicators of the quality
of care.40 A study comparing mortality of HIV-
infected patients starting ART in sub-Saharan Africa
with background mortality in Coˆte d’Ivoire, Malawi,
South Africa and Zimbabwe used estimates of
HIV-unrelated mortality rates from WHO’s Global
Burden of Disease project.36 Finally, IeDEA West
Africa documented important differences in treatment
response in patients infected with HIV-1 and HIV-2,
with implications for future treatment guidelines.1
What are the main strengths and
weaknesses?
The IeDEA networks in Africa provide a unique plat-
form for operational and clinical research that is
highly relevant to the scale-up of ART in
sub-Saharan Africa. The large number of participating
sites and large number of patients followed in high
burden countries are important strengths allowing for
determination of outcomes at the individual and pro-
gramme level. The data reflect routine care across the
range of care settings: urban and rural clinics, large
and very large programmes run by national health
systems, smaller clinics run by non-governmental or-
ganizations, and private clinics. The data undergo
considerable data cleaning, and the regional teams
work closely with clinic staff to understand and cor-
rect data quality problems. The AMPATH programme
in East Africa provides next day access to study data
and individual patient temporal trend graphs, for in-
stance weight and CD4 count, to improve clinical
management. These graphs are put in patient charts
after data entry so that they are readily available and
interpretable. By making data relevant to clinic per-
sonnel, the consortium strengthens the relevance of
data and increases clinical commitment to collection.
The service delivery models, clinical protocols, moni-
toring schedules and efforts in place to trace patients
lost to follow-up vary widely between sites. This di-
versity of data gives IeDEA substantial ability to gen-
eralize findings across different care delivery settings.
The data collected within IeDEA are observational
and causal inferences are challenging. Furthermore,
participation in IeDEA indicates that the facility has
Table 3 The three most common antiretroviral first-line regimens used in facilities enrolled in the four African regions of
the IeDEA, 2000–10
Anti-retroviral
regimen
West Africa Central Africa East Africa Southern Africa
Rank
No. on
regimen (%) Rank
No. on
regimen (%) Rank
No. on
regimen (%) Rank
No. on
regimen (%)
3TC-d4T-NVP 1 10 098 (30.3) 1 4374 (49.2) 1 36 418 (60.6) 1 66 369 (36.0)
AZT-3TC-NVP 2 5033 (15.1) 2 1745 (19.6) 2 7486 (12.4)
AZT-3TC-EFV 3 4992 (15.0) 3 696 (7.8) 3 4730 (7.9) 3 29 098 (15.8)
3TC-d4T-EFV 2 45 421 (24.6)
Other – 13 255 (39.6) – 2087 (23.4) – 11503 (19.1) – 43 498 (23.6)
3TC, lamivudine; d4T, stavudine; NVP, nevirapine; AZT, zidovudine; EFV, efavirenz.
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a certain level of capacity in data management and
patient follow-up. The participating programmes are
more likely than non-participating facilities to be
equipped with electronic medical record systems and
to have access to CD4 cell counts and second-line
therapy, which may reflect a higher clinical capacity
generally. Understanding the contextual variables
which differentiate IeDEA sites from other care facil-
ities is therefore important. Other weaknesses relate
to the quality of the data, with missing data in key
variables, varying definitions and data collection
protocols, and a high rate of loss to follow-up. In
the years to come, the African regions of IeDEA will
address these challenges by an iterative process of
quality improvement where those variables found to
be the most important are harmonized first and their
quality emphasized in data improvement efforts.
IeDEA will also perform dedicated multicentre studies
to address specific questions, and continue to develop
advanced statistical methods that can account for
missing data, loss to follow-up and competing risks,
and time-dependent confounding.
Where can I find out more?
The participating sites sign an agreement to allow
their data to be used in IeDEA, however, data own-
ership remains at the clinic level and all analyses have
to be approved by the regional Steering Groups and,
if analyses involve several regions, by the Executive
Committee of IeDEA. The IeDEA Executive
Committee is charged with facilitating data access
for all worthy research projects. We welcome collab-
orations with other cohort studies or cohort collabor-
ations, and other interested parties, for example
mathematical modelers or colleagues working in
international organizations. Readers who wish to
find out more should visit the IeDEA website
(www.iedea-hiv.org) where they will find contact de-
tails and links to the websites of the different regions.
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